⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 23, 2026Journal of Clinical PsychopharmacologyOpen Access

Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia

Yuki Mukai James Kost Linda Snow-adami Jessica Reed Theresa Taylor Justine Kent M. A. McEvoy Egan

View Full Paper

Ask AI

Bookmark

Share

Key Points

The primary aim is to assess the antipsychotic effects of the PDE10A inhibitor MK-8189 in individuals experiencing acute schizophrenia.
Conducted a Phase 2b clinical trial
Evaluated the effects of MK-8189 at specific doses
Focused on individuals with acute episodes of schizophrenia
No significant antipsychotic effects were observed at the tested doses
Findings suggest that PDE10A inhibition may not be beneficial in this context

Implication

This trial evaluates the antipsychotic effects of PDE10A inhibitor MK-8189 in schizophrenia, indicating a lack of effectiveness.

Abstract

These findings suggest that PDE10A inhibition does not have antipsychotic effects at the doses tested.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mukai et al. (2026) studied this question.

synapsesocial.com/papers/699e91eaf5123be5ed04fb91 https://doi.org/10.1097/jcp.0000000000002152

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial2024 · 20 citations
2Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of SchizophreniaOriginal Research · 2023 · 41 citations
3PDE10A Inhibitors—Clinical Failure or Window Into Antipsychotic Drug Action?Review · 2021 · 47 citations
4PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute SchizophreniaBlinded Clinical Trial · 2026
5PDE1B and PDE10A as novel targets for schizophrenia: from molecular design and synthesis to therapeutic promiseClinical Trial · 2026

More related papers

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study2024
Randomized, controlled, proof‐of‐concept trial of MK‐7622 in Alzheimer's disease2018
Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression2026

More from Journal of Clinical Psychopharmacology

Evaluation of the Effects of Different Doses of Ayahuasca on Intelligence and Verbal Memory in Healthy VolunteersMon,
Psychosis as an Adverse Effect of Antibiotics in Children and AdolescentsMon,